Can I Take Turmeric / Curcumin with Praluent (Alirocumab)?

How Alirocumab Is Processed in the Body

Alirocumab does not travel through the liver's cytochrome P450 enzyme system. It is a fully human IgG1 monoclonal antibody that binds PCSK9 in plasma and is then cleared through two parallel routes: target-mediated clearance (the alirocumab-PCSK9 complex is internalized by the LDL receptor) and non-specific IgG proteolytic catabolism in the reticuloendothelial system. The FDA Praluent prescribing information states that alirocumab "is not expected to be metabolized by cytochrome P450 enzymes."

Why CYP450 Metabolism Matters for Interactions

Most herb-drug interactions happen at CYP3A4, CYP2C9, or CYP1A2. Curcumin does inhibit CYP3A4 and CYP1A2 in vitro, as documented in a 2007 study by Appiah-Opong et al. Published in Toxicology. Because alirocumab bypasses these enzymes entirely, those inhibitory effects are irrelevant for this pairing.

P-glycoprotein and Transporter Interactions

Some supplements affect drug transporters such as P-glycoprotein (P-gp) and OATP1B1. Curcumin has shown P-gp inhibition in cell-based models, noted in a 2011 paper in Drug Metabolism and Disposition. Monoclonal antibodies like alirocumab are not substrates of these transporters. Transporter-based interactions therefore pose no clinical concern for this combination.

What Curcumin Actually Does Pharmacologically

Curcumin is the primary bioactive polyphenol in turmeric (Curcuma longa). It acts through several distinct pathways that are relevant when used alongside a lipid-lowering drug.

Anti-Inflammatory Mechanisms

Curcumin suppresses NF-kB signaling and reduces circulating IL-6 and TNF-alpha. A meta-analysis of 15 randomized controlled trials (N=728) published in Nutrition Journal found curcumin supplementation significantly reduced CRP (weighted mean difference: -6.44 mg/L, P<0.001). Because ASCVD itself is an inflammatory condition, this anti-inflammatory action is generally considered beneficial rather than harmful alongside Praluent.

Antiplatelet and Anticoagulant Properties

This is where clinical attention is warranted. Curcumin inhibits thromboxane B2 synthesis and reduces platelet aggregation in a dose-dependent manner. A 2012 study in Thrombosis Research showed that curcumin at 1 g/day reduced ADP-induced platelet aggregation by approximately 10 to 15% in healthy volunteers. At doses above 3 g/day of curcuminoids, the antiplatelet signal strengthens and becomes clinically relevant, particularly in patients already prescribed aspirin, clopidogrel, or warfarin alongside Praluent.

Lipid-Modifying Effects

A 2017 meta-analysis of 7 trials (N=649) published in Nutrition Journal found curcumin supplementation reduced LDL cholesterol by a mean of 0.12 to 0.22 mmol/L (approximately 5 to 8.5 mg/dL). Alirocumab 75 to 150 mg subcutaneously every two weeks reduced LDL-C by 46 to 61% from baseline in the ODYSSEY LONG TERM trial (N=2,341) published in the New England Journal of Medicine. The LDL-lowering contributions are not additive in a dangerous sense. Curcumin's modest effect sits on top of alirocumab's dominant mechanism without opposing it.

The Interaction Risk: Pharmacodynamic, Not Pharmacokinetic

The real interaction concern is pharmacodynamic: both curcumin and certain co-prescribed cardiovascular agents share antiplatelet properties. Alirocumab itself does not affect platelet function. The risk triangle is: high-dose curcumin + alirocumab patient who is also on aspirin or a P2Y12 inhibitor.

Bleeding Risk in Context

The ODYSSEY OUTCOMES trial (N=18,924), published in the New England Journal of Medicine, reported that alirocumab did not independently increase bleeding versus placebo. Curcumin alone at dietary doses (less than 500 mg/day curcuminoids) has not been associated with spontaneous bleeding in published trials. The signal for meaningful bleeding appears mainly when curcumin exceeds 1 to 3 g/day of standardized curcuminoid extract in patients on dual antiplatelet therapy, based on the antiplatelet data referenced in Thrombosis Research.

When the Risk Becomes Meaningful

Three clinical scenarios raise concern:

1. The patient takes alirocumab plus aspirin 81 mg plus a P2Y12 inhibitor (triple antiplatelet-adjacent coverage) and adds high-dose curcumin.
2. The patient is on alirocumab plus warfarin for concurrent atrial fibrillation and adds curcumin, which may weakly inhibit CYP2C9, the primary warfarin-metabolizing enzyme, as described in data compiled by the NIH Office of Dietary Supplements.
3. The patient has a history of gastrointestinal bleeding and exceeds 2 g/day of curcuminoids.

Dietary turmeric used in cooking (typically 0.1 to 0.4 g of curcuminoids per serving) does not approach these thresholds and is not a clinical concern.

Bioavailability: Why Dose Matters More Than the Label

Standard curcumin powder has notoriously poor oral bioavailability. Curcumin is rapidly conjugated and excreted, achieving plasma concentrations in the nanomolar range after a 1 g dose of plain curcumin. Bioenhanced formulations change this substantially.

Piperine-Enhanced and Lipid-Based Formulations

Piperine (BioPerine) at 20 mg co-administered with 2 g curcumin increased bioavailability by 2,000% in a pharmacokinetic study published in Planta Medica. Lipid-based forms (phytosome, nanoemulsion, SLCP) raise plasma curcuminoid concentrations by 5- to 29-fold compared to plain powder, as reviewed in Molecules. A patient taking a high-bioavailability curcumin product may reach plasma exposures equivalent to several grams of plain powder. Prescribers and pharmacists need the product name and formulation type, not just the label dose.

Practical Dose Thresholds

• Dietary turmeric in food: no interaction concern.
• Plain curcumin powder, 500 mg/day or less: minimal concern.
• Plain curcumin, 1 to 3 g/day: low concern unless anticoagulants are co-prescribed.
• Bioenhanced curcumin (piperine, phytosome, nanoemulsion), any dose above 500 mg/day: treat as higher effective dose and discuss with prescriber.
• Any curcumin formulation above 3 g/day in patients on antiplatelets or anticoagulants: warrants prescriber review before continuing.

What the Guidelines Say

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction, published in the Journal of the American College of Cardiology, does not specifically address curcumin but recommends that clinicians "review all prescription medications, over-the-counter drugs, and dietary supplements at each visit" for patients on lipid-lowering therapy.

The Natural Medicines Database (the successor to the Natural Standard) rates the interaction between turmeric and anticoagulant or antiplatelet drugs as "moderate" and notes that turmeric "may slow blood clotting" based on in vitro and limited human data. That rating applies to the pharmacodynamic overlap with co-prescribed agents, not to alirocumab itself.

The Endocrine Society's 2017 Dyslipidemia Guidelines, published in the Journal of Clinical Endocrinology and Metabolism, state that PCSK9 inhibitors have "no known drug-drug interactions" attributable to metabolic enzyme competition, consistent with alirocumab's mechanism-based safety profile.

Monitoring Recommendations

Patients taking alirocumab who choose to use curcumin supplements do not need additional lipid or hepatic monitoring beyond what their prescriber already schedules. Specific monitoring considerations include:

If No Antiplatelet or Anticoagulant Is Co-Prescribed

Routine monitoring is sufficient. Report any unusual bruising, prolonged bleeding from minor cuts, or gastrointestinal symptoms (dark stool, blood in stool) to a clinician promptly.

If Aspirin or a P2Y12 Inhibitor Is Co-Prescribed

Tell your cardiologist or prescriber about the curcumin supplement. For patients on dual antiplatelet therapy, most clinicians will recommend limiting curcumin to dietary sources or plain powder at 500 mg/day or less unless a specific clinical benefit justifies higher dosing. A baseline platelet function test (PFA-100 or VerifyNow) may be ordered before starting high-dose curcumin, as per institutional cardiology practice.

If Warfarin Is Co-Prescribed

INR should be rechecked 7 to 14 days after starting, stopping, or changing the curcumin dose. Curcumin's weak CYP2C9 inhibition could theoretically increase warfarin exposure, shifting the INR upward. A case report in the Annals of Pharmacotherapy documented an elevated INR in a patient taking turmeric alongside warfarin, supporting the need for closer INR tracking in this subset.

Does Curcumin Affect Alirocumab Efficacy?

No published clinical evidence shows curcumin reduces alirocumab's LDL-lowering efficacy. The PCSK9-binding mechanism is entirely extracellular and immune-mediated. There is no identified pathway by which curcumin would reduce antibody-antigen binding affinity, alter subcutaneous absorption of alirocumab, or accelerate its clearance. The ODYSSEY LONG TERM trial reported that alirocumab 150 mg every two weeks produced a 61% mean reduction in LDL-C at week 24 NEJM, N=2,341. That efficacy outcome would not be expected to change with concurrent curcumin use.

A 2018 network meta-analysis in JAMA Cardiology confirmed PCSK9 inhibitors including alirocumab produced a 15% reduction in major cardiovascular events (odds ratio 0.85, 95% CI 0.80 to 0.90, P<0.001) compared to control. Losing that cardiovascular benefit due to a supplement interaction is not a demonstrated risk with curcumin, but non-adherence to the alirocumab injection schedule is.

Curcumin's Potential Benefits in ASCVD Patients

Patients prescribed Praluent typically have established ASCVD or familial hypercholesterolemia. Some human trial evidence suggests curcumin may benefit this population through pathways beyond LDL reduction.

Endothelial Function

A randomized trial (N=32) in postmenopausal women published in Nutrition Research found that 150 mg/day of curcumin for 8 weeks improved brachial artery flow-mediated dilation by 2.8 percentage points (P<0.05), a marker of endothelial function relevant to ASCVD outcomes.

Oxidative Stress Markers

A meta-analysis of 11 RCTs (N=534) published in Pharmacological Research found curcumin supplementation significantly reduced malondialdehyde (a lipid peroxidation marker) by a standardized mean difference of -1.59 (P<0.001). Reduced oxidative stress may complement the cardiovascular risk reduction alirocumab provides through LDL lowering.

Blood Pressure

A 2019 meta-analysis of 11 trials (N=637) in Complementary Therapies in Medicine found curcumin reduced systolic blood pressure by a mean of 1.24 mmHg (P=0.04). That effect is modest, but directionally consistent with cardiovascular risk reduction goals in ASCVD patients.

What to Tell Your Prescriber

Disclosure of all supplements at every visit is the standard of care, per ACC/AHA 2022 guidelines. When you speak to your cardiologist or Praluent prescriber about curcumin, bring:

1. The product brand name and formulation type (plain powder, phytosome, piperine-enhanced, nanoemulsion).
2. The daily dose in milligrams of curcuminoids (not just turmeric root weight).
3. A list of every other medication, including aspirin, clopidogrel, and warfarin.
4. Any symptoms of unusual bleeding or bruising since starting curcumin.

Your prescriber can then assign a risk tier and decide whether to monitor, modify the curcumin dose, or continue without change.